RA Capital Management bought 9,078,529 derivative securities in Tyra Biosciences at $22.03 per share on Sep. 15, taking its holding to 11,616,986. The purchase represented about 78.1% of RA Capital Management’s resulting derivative securities position, giving investors a stated measure of the transaction’s size within its post-purchase holding.

Key Highlights

  • RA Capital Management’s post-transaction position in Tyra Biosciences stood at 11,616,986 derivative securities.
  • The purchase price was $22.03 per share on Sep. 15, 2026.
  • Transaction code P identifies the activity as an open-market purchase.

Tyra Biosciences, Inc. (NASDAQ: TYRA) is a biotechnology company. RA Capital Management, L.P. purchased 9,078,529 derivative securities in Tyra Biosciences at $22.03 per share on Sep. 15, lifting its resulting position to 11,616,986 derivative securities.

RA Capital Management Buys 9,078,529 Securities

The acquired securities were derivative securities of Tyra Biosciences, and the stated price was $22.03 per share.

Purchase Represents 78.1% of Resulting Holding

RA Capital Management’s resulting derivative securities position was 11,616,986. The transaction represented about 78.1% of that post-purchase holding. The transaction date was Sep. 15, 2026. The reported details pair the purchase with a per-share price of $22.03 and identify RA Capital Management, L.P. as the insider involved.